High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura: Protocol for a multicenter, open-label, single arm trial

Ken Takase; Akiko Kada; Hiromi Iwasaki; Isao Yoshida; Morio Sawamura; Nobuyuki Yoshio; Shinichiro Yoshida; Hiroatsu Iida; Maki Otsuka; Toshiro Takafuta; Yuko Ogata; Youko Suehiro; Yukio Hirabayashi; Terutoshi Hishita; Chikamasa Yoshida; Takuo Ito; Michihiro Hidaka; Ikuyo Tsutsumi; Akiko M. Saito; Hirokazu Nagai

High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura: Protocol for a multicenter, open-label, single arm trial

Ken Takase
, Akiko Kada
, Hiromi Iwasaki
, Isao Yoshida
, Morio Sawamura
, Nobuyuki Yoshio
, Shinichiro Yoshida
, Hiroatsu Iida
, Maki Otsuka
, Toshiro Takafuta
, Yuko Ogata
, Youko Suehiro
, Yukio Hirabayashi
, Terutoshi Hishita
, Chikamasa Yoshida
, Takuo Ito
, Michihiro Hidaka
, Ikuyo Tsutsumi
, Akiko M. Saito
, Hirokazu Nagai

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

抄録

Standard therapy for idiopathic thrombocytopenic purpura (ITP) has not been established. We are conducting a multicenter, prospective trial to determine the efficacy and safety of short-term, high-dose dexamethasone therapy in ITP patients aged 18-80 years with platelet counts of < 20, 000 /μL, or with < 50, 000/ μL and bleeding symptoms. The primary endpoints of this trial are the proportion of responses (complete plus partial response) on day 180 (day 46+180) after the completion of the 46-day high-dose dexamethasone therapy. The results of this investigation of the effectiveness and safety of this regimen will be essential for the establishment of standard therapy for ITP.

本文言語	英語
ページ（範囲）	197-201
ページ数	5
ジャーナル	Acta Medica Okayama
巻	72
号	2
出版ステータス	出版済み - 2018
外部発表	はい

All Science Journal Classification (ASJC) codes

生化学、遺伝学、分子生物学一般

他のファイルとリンク

フィンガープリント

「High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura: Protocol for a multicenter, open-label, single arm trial」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Takase, K., Kada, A., Iwasaki, H., Yoshida, I., Sawamura, M., Yoshio, N., Yoshida, S., Iida, H., Otsuka, M., Takafuta, T., Ogata, Y., Suehiro, Y., Hirabayashi, Y., Hishita, T., Yoshida, C., Ito, T., Hidaka, M., Tsutsumi, I., Saito, A. M., & Nagai, H. (2018). High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura: Protocol for a multicenter, open-label, single arm trial. Acta Medica Okayama, 72(2), 197-201.

@article{e1f3e6bc8d4f4511beb332679e2b2d24,

title = "High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura: Protocol for a multicenter, open-label, single arm trial",

abstract = "Standard therapy for idiopathic thrombocytopenic purpura (ITP) has not been established. We are conducting a multicenter, prospective trial to determine the efficacy and safety of short-term, high-dose dexamethasone therapy in ITP patients aged 18-80 years with platelet counts of < 20, 000 /μL, or with < 50, 000/ μL and bleeding symptoms. The primary endpoints of this trial are the proportion of responses (complete plus partial response) on day 180 (day 46+180) after the completion of the 46-day high-dose dexamethasone therapy. The results of this investigation of the effectiveness and safety of this regimen will be essential for the establishment of standard therapy for ITP.",

author = "Ken Takase and Akiko Kada and Hiromi Iwasaki and Isao Yoshida and Morio Sawamura and Nobuyuki Yoshio and Shinichiro Yoshida and Hiroatsu Iida and Maki Otsuka and Toshiro Takafuta and Yuko Ogata and Youko Suehiro and Yukio Hirabayashi and Terutoshi Hishita and Chikamasa Yoshida and Takuo Ito and Michihiro Hidaka and Ikuyo Tsutsumi and Saito, \{Akiko M.\} and Hirokazu Nagai",

note = "Publisher Copyright: {\textcopyright} 2018 by Okayama University Medical School.",

year = "2018",

language = "English",

volume = "72",

pages = "197--201",

journal = "Acta Medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "2",

}

Takase, K, Kada, A, Iwasaki, H, Yoshida, I, Sawamura, M, Yoshio, N, Yoshida, S, Iida, H, Otsuka, M, Takafuta, T, Ogata, Y, Suehiro, Y, Hirabayashi, Y, Hishita, T, Yoshida, C, Ito, T, Hidaka, M, Tsutsumi, I, Saito, AM & Nagai, H 2018, 'High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura: Protocol for a multicenter, open-label, single arm trial', Acta Medica Okayama, vol. 72, no. 2, pp. 197-201.

TY - JOUR

T1 - High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura

T2 - Protocol for a multicenter, open-label, single arm trial

AU - Takase, Ken

AU - Kada, Akiko

AU - Iwasaki, Hiromi

AU - Yoshida, Isao

AU - Sawamura, Morio

AU - Yoshio, Nobuyuki

AU - Yoshida, Shinichiro

AU - Iida, Hiroatsu

AU - Otsuka, Maki

AU - Takafuta, Toshiro

AU - Ogata, Yuko

AU - Suehiro, Youko

AU - Hirabayashi, Yukio

AU - Hishita, Terutoshi

AU - Yoshida, Chikamasa

AU - Ito, Takuo

AU - Hidaka, Michihiro

AU - Tsutsumi, Ikuyo

AU - Saito, Akiko M.

AU - Nagai, Hirokazu

PY - 2018

Y1 - 2018

N2 - Standard therapy for idiopathic thrombocytopenic purpura (ITP) has not been established. We are conducting a multicenter, prospective trial to determine the efficacy and safety of short-term, high-dose dexamethasone therapy in ITP patients aged 18-80 years with platelet counts of < 20, 000 /μL, or with < 50, 000/ μL and bleeding symptoms. The primary endpoints of this trial are the proportion of responses (complete plus partial response) on day 180 (day 46+180) after the completion of the 46-day high-dose dexamethasone therapy. The results of this investigation of the effectiveness and safety of this regimen will be essential for the establishment of standard therapy for ITP.

AB - Standard therapy for idiopathic thrombocytopenic purpura (ITP) has not been established. We are conducting a multicenter, prospective trial to determine the efficacy and safety of short-term, high-dose dexamethasone therapy in ITP patients aged 18-80 years with platelet counts of < 20, 000 /μL, or with < 50, 000/ μL and bleeding symptoms. The primary endpoints of this trial are the proportion of responses (complete plus partial response) on day 180 (day 46+180) after the completion of the 46-day high-dose dexamethasone therapy. The results of this investigation of the effectiveness and safety of this regimen will be essential for the establishment of standard therapy for ITP.

UR - https://www.scopus.com/pages/publications/85047184760

UR - https://www.scopus.com/pages/publications/85047184760#tab=citedBy

M3 - Article

C2 - 29674771

AN - SCOPUS:85047184760

SN - 0386-300X

VL - 72

SP - 197

EP - 201

JO - Acta Medica Okayama

JF - Acta Medica Okayama

IS - 2

ER -